Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL
The U.S. Food and Drug Administration (FDA) has approved the cell therapy Aucatzyl (obecabtagene autoleucel) to treat adults with relapsed or refractory precursor B-cell acute…
News
Doctors ID rare pancreatic neuroendocrine tumor in girl, 17
Doctors should consider the possibility of a pancreatic neuroendocrine tumor (pNET) when patients with a history of abdominal and back pain seek treatment. That’s…
Virus-based MB-108 named FDA orphan drug for malignant glioma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-108, an experimental virus-based therapy that Mustang Bio is developing for…
Ovarian cancer lessens efficacy of T-cell immunotherapy, study finds
The microenvironment of ovarian cancer tumors actively suppress the work of immune T-cells by blocking their energy supply, a study reports. These findings have implications…
Stem cell transplant is safe, effective in myeloma: Global real-world study
A standard autologous hematopoietic stem cell transplant (AHSCT) safely and effectively prolongs survival and delays cancer progression in adults with multiple myeloma, a…
Darzalex combo OK’d for multiple myeloma transplant-eligible patients
The subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has been approved in the European Union as part of a combination treatment for adults with newly…
Darzalex combo up for EU approval for multiple myeloma patients
Johnson & Johnson (J&J) is asking regulatory authorities in the European Union to approve a combination treatment based on the subcutaneous, or under-the-skin, formulation…
Carvykti found effective at treating multiple myeloma in real world
Real-world treatment with the cell therapy Carvykti (ciltacabtagene autoleucel) was found to be highly effective among people with difficult-to-treat multiple myeloma in a multicenter…
New US approval sought for Darzalex Faspro quadruple therapy
Johnson & Johnson (J&J) is seeking U.S. Food and Drug Administration (FDA) approval for a quadruple treatment regimen based on Darzalex Faspro (daratumumab…
Carvykti lowering risk of death as second-line myeloma therapy: Trial
A single infusion of the cell therapy Carvykti (ciltacabtagene autoleucel) reduced the risk of death by 45% relative to standard treatment regimens for multiple…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML